Healthcare Sales & Marketing Network News: LY-CoV555

Searching News Database: LY-CoV555

HSMN NewsFeed - 16 Apr 2021
Lilly requests revocation of emergency use authorization for bamlanivimab alone to complete transition to bamlanivimab and etesevimab together for treatment of COVID-19 in the U.S.
Biopharmaceuticals FDA

HSMN NewsFeed - 26 Feb 2021
Lilly announces additional doses of neutralizing antibody therapy purchased by U.S. government to treat COVID-19
Biopharmaceuticals

HSMN NewsFeed - 28 Oct 2020
Lilly announces agreement with U.S. government to supply 300,000 vials of investigational neutralizing antibody bamlanivimab (LY-CoV555) in an effort to fight COVID-19
Biopharmaceuticals

HSMN NewsFeed - 7 Oct 2020
Lilly provides comprehensive update on progress of SARS-CoV-2 neutralizing antibody programs
Biopharmaceuticals

HSMN NewsFeed - 3 Aug 2020
Lilly Initiates Phase 3 Trial of LY-CoV555 for Prevention of COVID-19 at Long-Term Care Facilities in Partnership with the National Institute of Allergy and Infectious Diseases (NIAID)
Biopharmaceuticals

HSMN NewsFeed - 8 Jun 2020
Lilly Announces Start of a Phase 1 Study for its Second Potential COVID-19 Antibody Treatment
Biopharmaceuticals

HSMN NewsFeed - 1 Jun 2020
Lilly Begins World's First Study of a Potential COVID-19 Antibody Treatment in Humans
Biopharmaceuticals

Return to NewsFeed

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.

FindReps - available on the Apple App Store for iPhone and iPad.